Beryl Drugs Intrinsic Value
Beryl Drugs intrinsic value. Beryl Drugs (BERLDRG) median intrinsic value is ₹26.40 from 9 valuation models (range ₹8–₹62), vs current price ₹24.84 — +6.3% upside (Trading Near Calculated Value), margin of safety 5.9%. Read BERLDRG dividend track record for the complete payout history and dividend yield track record.
BERLDRG Valuation Methods Summary — DCF, Graham Number & P/E
Beryl Drugs intrinsic value across 9 models vs current price ₹24.84 — upside/downside and value range per method. Compare with BERLDRG DCF valuation to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹26.40 | ₹21.12 - ₹31.68 | +6.3% | EPS: ₹1.20, Sector P/E: 22x |
| Book Value Method | asset | ₹40.00 | ₹36.00 - ₹44.00 | +61.0% | Book Value/Share: ₹20.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹49.68 | ₹44.71 - ₹54.65 | +100.0% | Revenue/Share: ₹44.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹40.00 | ₹36.00 - ₹44.00 | +61.0% | EBITDA: ₹2.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹62.10 | ₹49.68 - ₹74.52 | +150.0% | CF Growth: 10.1%, Discount: 15% |
| PEG Ratio Method | growth | ₹7.68 | ₹6.91 - ₹8.45 | -69.1% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹17.55 | ₹15.80 - ₹19.31 | -29.3% | Revenue Growth: -5.0%, Adj P/E: 14.6x |
| ROE Based Valuation | profitability | ₹20.00 | ₹18.00 - ₹22.00 | -19.5% | ROE: 10.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹23.24 | ₹20.92 - ₹25.56 | -6.4% | EPS: ₹1.20, BVPS: ₹20.00 |
BERLDRG Intrinsic Value vs Market Price — All Valuation Models
Beryl Drugs fair value range ₹8–₹62 vs current market price ₹24.84 across 9 valuation models. For current market price and key ratios, visit Beryl Drugs screener.
BERLDRG Intrinsic Value Analysis — Undervalued or Overvalued?
Beryl Drugs median intrinsic value ₹26.40, current price ₹24.84 — Trading Near Calculated Value by 6.3%, margin of safety 5.9%.
What is the intrinsic value of BERLDRG?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Beryl Drugs (BERLDRG) is ₹26.40 (median value). With the current market price of ₹24.84, this represents a +6.3% variance from our estimated fair value.
The valuation range spans from ₹7.68 to ₹62.10, indicating ₹7.68 - ₹62.10.
Is BERLDRG undervalued or overvalued?
Based on our multi-method analysis, Beryl Drugs (BERLDRG) appears to be trading near calculated value by approximately 6.3%.
BERLDRG Financial Health — Key Ratios vs Industry Benchmarks
Beryl Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 10.0% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 8.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.47x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
BERLDRG Cash Flow Quality — Operating & Free Cash Flow
Beryl Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |